The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
20 07 2022
Historique:
received: 10 06 2022
revised: 11 07 2022
accepted: 13 07 2022
entrez: 25 7 2022
pubmed: 26 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

Brain metastases (BMs) in patients with extra-pulmonary neuroendocrine neoplasms (EP-NENs) are rare, and limited clinical information is available. The aim of this study was to detail the clinicopathological features, management and outcomes in patients with EP-NENs who developed BMs. A retrospective single-centre analysis of consecutive patients with EP-NENs (August 2004-February 2020) was conducted. Median overall survival (OS)/survival from BMs diagnosis was estimated (Kaplan-Meier). Of 730 patients, 17 (1.9%) had BMs, median age 61 years (range 15-77); 8 (53%) male, unknown primary NEN site: 40%. Patients with BMs had grade 3 (G3) EP-NENs 11 (73%), G2: 3 (20%), G1: 1 (7%). Eight (53%) had poorly differentiated NENs, 6 were well-differentiated and 1 was not recorded. Additionally, 2 (13%) patients had synchronous BMs at diagnosis, whilst 13 (87%) developed BMs metachronously. The relative risk of developing BMs was 7.48 in patients with G3 disease vs. G1 + G2 disease ( BMs in patients with EP-NENs are rare and of increased risk in G3 vs. G1 + G2 EP-NENs. Survival outcomes are poor, and a greater understanding is needed to improve therapeutic outcomes.

Sections du résumé

BACKGROUND
Brain metastases (BMs) in patients with extra-pulmonary neuroendocrine neoplasms (EP-NENs) are rare, and limited clinical information is available. The aim of this study was to detail the clinicopathological features, management and outcomes in patients with EP-NENs who developed BMs.
METHODS
A retrospective single-centre analysis of consecutive patients with EP-NENs (August 2004-February 2020) was conducted. Median overall survival (OS)/survival from BMs diagnosis was estimated (Kaplan-Meier).
RESULTS
Of 730 patients, 17 (1.9%) had BMs, median age 61 years (range 15-77); 8 (53%) male, unknown primary NEN site: 40%. Patients with BMs had grade 3 (G3) EP-NENs 11 (73%), G2: 3 (20%), G1: 1 (7%). Eight (53%) had poorly differentiated NENs, 6 were well-differentiated and 1 was not recorded. Additionally, 2 (13%) patients had synchronous BMs at diagnosis, whilst 13 (87%) developed BMs metachronously. The relative risk of developing BMs was 7.48 in patients with G3 disease vs. G1 + G2 disease (
CONCLUSION
BMs in patients with EP-NENs are rare and of increased risk in G3 vs. G1 + G2 EP-NENs. Survival outcomes are poor, and a greater understanding is needed to improve therapeutic outcomes.

Identifiants

pubmed: 35877265
pii: curroncol29070405
doi: 10.3390/curroncol29070405
pmc: PMC9319979
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5110-5125

Références

N Engl J Med. 1999 Aug 12;341(7):476-84
pubmed: 10441603
Ann Oncol. 2013 Jan;24(1):152-60
pubmed: 22967994
Lancet. 2004 May 22;363(9422):1665-72
pubmed: 15158627
Neuroendocrinology. 2017;104(2):105-111
pubmed: 26505990
Am J Surg Pathol. 2008 May;32(5):719-31
pubmed: 18360283
BMC Cancer. 2016 Apr 01;16:260
pubmed: 27037031
J Thorac Dis. 2020 Oct;12(10):6234-6239
pubmed: 33209462
Neuroendocrinology. 2020;110(7-8):688-696
pubmed: 31639796
J Clin Oncol. 2000 Oct 1;18(19):3400-8
pubmed: 11013281
J Neurosurg. 2016 Dec;125(Suppl 1):11-17
pubmed: 27903179
Clin Transl Radiat Oncol. 2021 Dec 02;32:52-58
pubmed: 34926839
N Engl J Med. 2007 Aug 16;357(7):664-72
pubmed: 17699816
J Clin Oncol. 2022 Feb 10;40(5):492-516
pubmed: 34932393
Cancers (Basel). 2021 Mar 12;13(6):
pubmed: 33809007
Neuroendocrinology. 2021;111(11):1111-1120
pubmed: 33227805
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
Radiother Oncol. 1998 Jan;46(1):29-32
pubmed: 9488124
J Thorac Oncol. 2013 Sep;8(9):1215-21
pubmed: 23945390
JAMA Oncol. 2020 Jul 1;6(7):1028-1037
pubmed: 32496550
BMC Cancer. 2019 Apr 16;19(1):362
pubmed: 30991982
Eur Arch Otorhinolaryngol. 2016 Oct;273(10):2925-30
pubmed: 26530293
BMC Cancer. 2001;1:5
pubmed: 11432756
Pancreas. 2010 Aug;39(6):799-800
pubmed: 20664477
Clin Transl Oncol. 2019 Jul;21(7):950-953
pubmed: 30506132
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1001-6
pubmed: 10863071
Acta Oncol. 2019 Apr;58(4):499-504
pubmed: 30732516
BMC Endocr Disord. 2020 Apr 3;20(1):44
pubmed: 32245472
Lancet. 2016 Oct 22;388(10055):2004-2014
pubmed: 27604504
Cancer Med. 2019 Dec;8(17):7288-7298
pubmed: 31609098

Auteurs

Zainul-Abedin Kapacee (ZA)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Jennifer Allison (J)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Mohammed Dawod (M)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Xin Wang (X)

Statistics Group, Digital Services, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Melissa Frizziero (M)

Cancer Research UK Manchester Institute, University of Manchester, Manchester M20 4BX, UK.

Bipasha Chakrabarty (B)

Department of Pathology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Prakash Manoharan (P)

Department of Nuclear Medicine/Radiology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Catherine McBain (C)

Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Was Mansoor (W)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Angela Lamarca (A)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Richard Hubner (R)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Juan W Valle (JW)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK.

Mairéad G McNamara (MG)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH